NLS Pharmaceutics (NASDAQ:NCEL) Trading 2.2% Higher – Should You Buy?

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) shares traded up 2.2% on Wednesday . The stock traded as high as $3.31 and last traded at $3.25. 4,901 shares traded hands during trading, a decline of 93% from the average session volume of 67,647 shares. The stock had previously closed at $3.18.

NLS Pharmaceutics Trading Up 2.2%

The firm’s 50 day moving average price is $2.88 and its two-hundred day moving average price is $3.00.

Insider Activity

In other NLS Pharmaceutics news, Director Olivier Samuel bought 81,818 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was acquired at an average price of $2.75 per share, for a total transaction of $224,999.50. Following the completion of the purchase, the director owned 81,818 shares of the company’s stock, valued at approximately $224,999.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michel Revel bought 54,545 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $2.75 per share, with a total value of $149,998.75. Following the purchase, the director directly owned 957,530 shares of the company’s stock, valued at approximately $2,633,207.50. This trade represents a 6.04% increase in their position. The SEC filing for this purchase provides additional information. 16.40% of the stock is currently owned by corporate insiders.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.